Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
    • Editorial Fellowship Application Process
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Clinical Research
You have accessRestricted Access

Sodium Intake, ACE Inhibition, and Progression to ESRD

Stefan Vegter, Annalisa Perna, Maarten J. Postma, Gerjan Navis, Giuseppe Remuzzi and Piero Ruggenenti
JASN January 2012, 23 (1) 165-173; DOI: https://doi.org/10.1681/ASN.2011040430
Stefan Vegter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annalisa Perna
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarten J. Postma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerjan Navis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppe Remuzzi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piero Ruggenenti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

High sodium intake limits the antihypertensive and antiproteinuric effects of angiotensin-converting enzyme (ACE) inhibitors in patients with CKD; however, whether dietary sodium also associates with progression to ESRD is unknown. We conducted a post hoc analysis of the first and second Ramipril Efficacy in Nephropathy trials to evaluate the association of sodium intake with proteinuria and progression to ESRD among 500 CKD patients without diabetes who were treated with ramipril (5 mg/d) and monitored with serial 24-hour urinary sodium and creatinine measurements. Urinary sodium/creatinine excretion defined low (<100 mEq/g), medium (100 to <200 mEq/g), and high (≥200 mEq/g) sodium intake. During a follow-up of >4.25 years, 92 individuals (18.4%) developed ESRD. Among those with low, medium, and high sodium intakes, the incidence of ESRD was 6.1 (95% confidence interval [95% CI], 3.8–9.7), 7.9 (95% CI, 6.1–10.2), and 18.2 (95% CI, 11.3–29.3) per 100 patient-years, respectively (P<0.001). Patients with high dietary sodium exhibited a blunted antiproteinuric effect of ACE inhibition despite similar BP among groups. Each 100-mEq/g increase in urinary sodium/creatinine excretion associated with a 1.61-fold (95% CI, 1.15–2.24) higher risk for ESRD; adjusting for baseline proteinuria attenuated this association to 1.38-fold (95% CI, 0.95–2.00). This association was independent from BP but was lost after adjusting for changes in proteinuria. In summary, among patients with CKD but without diabetes, high dietary salt (>14 g daily) seems to blunt the antiproteinuric effect of ACE inhibitor therapy and increase the risk for ESRD, independent of BP control.

  • Copyright © 2012 by the American Society of Nephrology
View Full Text
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 23 (1)
Journal of the American Society of Nephrology
Vol. 23, Issue 1
1 Jan 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Sodium Intake, ACE Inhibition, and Progression to ESRD
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Sodium Intake, ACE Inhibition, and Progression to ESRD
Stefan Vegter, Annalisa Perna, Maarten J. Postma, Gerjan Navis, Giuseppe Remuzzi, Piero Ruggenenti
JASN Jan 2012, 23 (1) 165-173; DOI: 10.1681/ASN.2011040430

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Sodium Intake, ACE Inhibition, and Progression to ESRD
Stefan Vegter, Annalisa Perna, Maarten J. Postma, Gerjan Navis, Giuseppe Remuzzi, Piero Ruggenenti
JASN Jan 2012, 23 (1) 165-173; DOI: 10.1681/ASN.2011040430
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Concise Methods
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Impact of the COVID-19 Pandemic on Nephrology Fellow Training and Well-Being in the United States: A National Survey
  • Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection
  • Kidney Function after Treatment for Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study
Show more Clinical Research

Cited By...

  • Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease
  • Dietary sodium restriction decreases urinary NGAL in older adults with moderately elevated systolic blood pressure free from chronic kidney disease
  • Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease
  • Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss
  • Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD
  • Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial
  • Social Determinants of Racial Disparities in CKD
  • Spot urine sodium measurements do not accurately estimate dietary sodium intake in chronic kidney disease
  • Urinary Sodium and Potassium Excretion and CKD Progression
  • Meta-Analysis of the Effect of Dietary Sodium Restriction with or without Concomitant Renin-Angiotensin-Aldosterone System-Inhibiting Treatment on Albuminuria
  • Urea and Ammonia Metabolism and the Control of Renal Nitrogen Excretion
  • Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View
  • Volume Overload and Adverse Outcomes in Chronic Kidney Disease: Clinical Observational and Animal Studies
  • Effects of Intensive Low-Salt Diet Education on Albuminuria among Nondiabetic Patients with Hypertension Treated with Olmesartan: A Single-Blinded Randomized, Controlled Trial
  • What Determines Human Sodium Intake: Policy or Physiology?
  • Association Between Urinary Sodium, Creatinine, Albumin, and Long-Term Survival in Chronic Kidney Disease
  • Intestinal Inhibition of the Na+/H+ Exchanger 3 Prevents Cardiorenal Damage in Rats and Inhibits Na+ Uptake in Humans
  • Sodium Excretion and Risk of Developing Coronary Heart Disease
  • Sodium Reduction in CKD: Suggestively Hazardous or Intuitively Advantageous?
  • Active Vitamin D Treatment for Reduction of Residual Proteinuria: A Systematic Review
  • High-protein diet in diabetic nephropathy: what is really safe?
  • Mechanisms and Treatment of CKD
  • Google Scholar

Similar Articles

Related Articles

  • Sodium Intake, ACE Inhibition, and Progression to ESRD
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire